EXXONMOBIL
12.9.2019 13:02:09 CEST | Business Wire | Press release
ExxonMobil announced today the global launch of its Mobil EV™ offering at the 2019 IAA, which features a full suite of fluids and greases designed to meet the evolving drivetrain requirements of battery electric vehicles. In combination, plug-in hybrids, battery electric and fuel cell vehicles are predicted to exceed 20 percent of the world’s light-duty fleet by 20401 .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005285/en/
“Mobility is changing and electric vehicles are becoming a greater part of the mix,” said Russ Green, ExxonMobil’s vice president of finished lubricants. “Customers and OEMs are looking to optimize the range and safety performance of their electric vehicles, and ExxonMobil is uniquely positioned to deliver these benefits. This is just the start of the product and service solutions we’ll be developing to support the evolving needs of our customers.”
Designed to support the electric vehicle mobility needs of manufacturers and drivers alike, the Mobil EV suite of products contains molecules carefully selected and blended to help battery electric vehicles travel further between charges, extend component life and operate more safely. Covering the full range of battery electric vehicle applications, the Mobil EV product range includes:
- Mobil EV Therm™ series of thermal management fluids, formulated to help efficiently remove heat and increase equipment life in applications such as batteries, electric motors, and power electronics.
- Mobil EV Drive™ series of lubricants for electric vehicle reduction gearboxes, designed to protect gears and bearings from wear for a longer service life.
- Mobil EV Cool Drive™ series of fluids for electric vehicle reduction gearboxes with integrated electric motors, designed to lubricate gears and bearings while providing the necessary cooling for electric motors and power electronics.
- Mobil EV Grease™ products ensuring protection, performance and reliability for electric vehicle applications including e-motors, bearings and constant velocity joints across a wide range of driving conditions.
Building on a more than 135-year heritage, ExxonMobil is committed to leveraging its fluids technology and equipment management expertise to help automobile and component manufacturers develop electric vehicles that deliver a superior driving experience for customers.
This launch follows the recent extension of the company’s partnership with Porsche to include collaboration on its Formula E series car for the 2019 / 2020 season – ExxonMobil’s first entry into electric motorsports. ExxonMobil will provide Mobil-branded high-performance electric powertrain fluids to Porsche, developed specifically to meet the specialized demands of electric vehicles – including conductivity, cooling capabilities and material compatibility.
For more information please visit: www.mobilev.com .
About ExxonMobil
ExxonMobil, the largest publicly traded international oil and gas company, uses technology and innovation to help meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is one of the largest refiners and marketers of petroleum products, and its chemical company is one of the largest in the world.
1 2019 Outlook for Energy: A Perspective to 2040 , ExxonMobil, 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005285/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom